- Home
- FSHP vs BLUE Comparison
FSHP vs BLUE Comparison
Compare FSHP & BLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FSHP
- BLUE
- Stock Information
- Founded
- FSHP 2018
- BLUE 1992
- Country
- FSHP United States
- BLUE United States
- Employees
- FSHP N/A
- BLUE N/A
- Industry
- FSHP
- BLUE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FSHP
- BLUE Health Care
- Exchange
- FSHP NYSE
- BLUE Nasdaq
- Market Cap
- FSHP 89.2M
- BLUE 78.7M
- IPO Year
- FSHP 2024
- BLUE 2013
- Fundamental
- Price
- FSHP $10.15
- BLUE $9.34
- Analyst Decision
- FSHP
- BLUE Hold
- Analyst Count
- FSHP 0
- BLUE 9
- Target Price
- FSHP N/A
- BLUE $49.14
- AVG Volume (30 Days)
- FSHP 35.0K
- BLUE 627.8K
- Earning Date
- FSHP 01-01-0001
- BLUE 11-14-2024
- Dividend Yield
- FSHP N/A
- BLUE N/A
- EPS Growth
- FSHP N/A
- BLUE N/A
- EPS
- FSHP 0.11
- BLUE N/A
- Revenue
- FSHP N/A
- BLUE $53,120,000.00
- Revenue This Year
- FSHP N/A
- BLUE $161.01
- Revenue Next Year
- FSHP N/A
- BLUE $221.61
- P/E Ratio
- FSHP $89.28
- BLUE N/A
- Revenue Growth
- FSHP N/A
- BLUE 144.50
- 52 Week Low
- FSHP $9.99
- BLUE $5.80
- 52 Week High
- FSHP $10.16
- BLUE $55.60
- Technical
- Relative Strength Index (RSI)
- FSHP N/A
- BLUE 54.68
- Support Level
- FSHP N/A
- BLUE $5.97
- Resistance Level
- FSHP N/A
- BLUE $10.20
- Average True Range (ATR)
- FSHP 0.00
- BLUE 1.81
- MACD
- FSHP 0.00
- BLUE 0.10
- Stochastic Oscillator
- FSHP 0.00
- BLUE 39.24
About FSHP FLAG SHIP ACQUISITION CORPORATION
Flag Ship Acquisition Corp is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.
About BLUE bluebird bio Inc.
bluebird bio Inc is a biotechnology company engaged in researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. The Company operates in a single segment, focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases.